about
Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancerUnderstanding the role of the kynurenine pathway in human breast cancer immunobiologyMiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast CancerBiomarkers in triple negative breast cancer: A reviewA recapitulative three-dimensional model of breast carcinoma requires perfusion for multi-week growthAndrogen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysisA perspective on anti-EGFR therapies targeting triple-negative breast cancerEstrogen-Related Receptors in Breast Cancer and Prostate CancermiR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancerPanepoxydone targets NF-kB and FOXM1 to inhibit proliferation, induce apoptosis and reverse epithelial to mesenchymal transition in breast cancerNovel genes associated with lymph node metastasis in triple negative breast cancerCyanidin-3-o-glucoside directly binds to ERα36 and inhibits EGFR-positive triple-negative breast cancerThe differences in ultrasound and clinicopathological features between basal-like and normal-like subtypes of triple negative breast cancer.Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status.An Integrative Genomics Approach for Associating GWAS Information with Triple-Negative Breast Cancer.Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer.A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer.Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumour grade and other prognostic factorsPea3 transcription factors and wnt1-induced mouse mammary neoplasiaRole of postmastectomy radiotherapy in early-stage (T1-2N0-1M0) triple-negative breast cancer: a systematic review.Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study.Breast cancer risk after radiotherapy for heritable and non-heritable retinoblastoma: a US-UK study.Hsp90 in the continuum of breast ductal carcinogenesis: Evaluation in precursors, preinvasive and ductal carcinoma lesionsFavorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotypeFOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer.Implications of differences in expression of sarcosine metabolism-related proteins according to the molecular subtype of breast cancer.Global gene expression changes induced by prolonged cold ischemic stress and preservation method of breast cancer tissue.Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells.Ets-1 is a transcriptional mediator of oncogenic nitric oxide signaling in estrogen receptor-negative breast cancer.Co-targeting the IGF system and HIF-1 inhibits migration and invasion by (triple-negative) breast cancer cells.Age-associated prognostic and predictive biomarkers in patients with breast cancer.Clinicopathological features and prognosis of triple negative breast cancer in Kuwait: A comparative/perspective analysis.High expression of CD147 and MMP-9 is correlated with poor prognosis of triple-negative breast cancer (TNBC) patientsThe role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment.Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets.Blueberry phytochemicals inhibit growth and metastatic potential of MDA-MB-231 breast cancer cells through modulation of the phosphatidylinositol 3-kinase pathway.Differential expression of enzymes associated with serine/glycine metabolism in different breast cancer subtypes.alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies.Triple negative breast cancer in a poor resource setting in North-Western Tanzania: a preliminary study of 52 patients
P2860
Q21261291-D815C33F-A496-404B-A295-9245099E8718Q24654216-418E8848-8BA8-4CBF-B447-B1CC29EF95E1Q26773472-B8384234-1880-4BF5-A5E3-6370FD96D4ECQ26775086-D468E1A2-5E68-42A4-8AF2-F5974DF7326AQ26775094-026165B7-A26B-4725-8389-1A06983467ABQ26779577-D30B0B49-7D5F-42B6-98B0-0F40EE48D836Q26823419-84B928EA-E79B-47C2-B10B-EAE506657E35Q28069867-C08AEB78-8F01-41CA-A15F-089FD873656DQ28084030-AE770B64-63B5-4AAA-8017-5E3A18ECEB3DQ28115315-E7E73995-7211-48EC-9553-72CE101B1604Q28387216-822BA84C-D612-474B-8044-74ABA064C9D2Q28393204-FA50E3BE-A666-4A48-9F28-45C171A5BA46Q29248648-EFA17348-B079-4109-9FC9-64CACD931F99Q30417120-10E43915-96B1-4C58-8D7C-D1C7E029931CQ30496322-72C0E5CA-A3CF-4654-A6E1-3BBC9BF3DE19Q33355327-FC6FA3CF-7F4A-43C0-9802-A66F6A667347Q33415281-8730C827-0DC6-4E9F-BDF5-C558AD53F648Q33420154-DBAD25CF-56AB-4BDC-9B91-C44C9628C7BFQ33483633-2D834439-D80A-4A0E-999E-0A8534C208B4Q33526975-51C12DDB-997D-4A9C-B03C-25202F8F3AD5Q33553668-4723672F-F288-4EDF-9048-89835CE14745Q33596695-9F60F3A6-37F5-4316-ACE8-55D32B2B8851Q33613662-1BF494D7-D35C-4AE5-B630-10761B2C31F3Q33625453-4A10671C-504C-43B1-942E-28810DFC55F2Q33710233-461539F1-E19A-4857-84B0-2E089A56526CQ33710341-AB7D393E-FA1B-48A5-9DED-D1982C85F1D5Q33712426-6B6A321B-F385-40E7-B7A0-453CC50DD537Q33723629-46ECF7F6-1571-473F-808F-9C49ACF037DAQ33726477-B8F1D42F-B3CD-4439-8628-9505EB8B4AE1Q33739233-89D1B812-8CC9-4B3B-95E6-D0849B938DBEQ33750192-ADC60BE0-90E0-4BB1-BD97-7129EAC7A215Q33750880-135469D2-058F-4467-BBB0-963482F2FCC3Q33751806-386DD9DB-0926-4260-ABC1-CBDEEFC2BFF1Q33762138-ED5D00CC-DE76-4452-9E8D-8996A0624633Q33776899-0C1C76B6-E8AD-46D6-86DA-0C9E63EDD08BQ33780945-552E6315-DA0E-40F2-B4D9-C3D3A24F939CQ33820727-B5F4B1AF-763F-4E49-9C1F-3F57B4CFB30EQ33825671-3409B612-34F2-4D86-B392-0961663A2951Q33830446-9723351F-E660-43BF-AEFC-793FE73C8916Q33842913-F3DFA301-4776-4E50-8457-CA0D7382D57F
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Triple negative tumours: a critical review.
@en
Triple negative tumours: a critical review.
@nl
type
label
Triple negative tumours: a critical review.
@en
Triple negative tumours: a critical review.
@nl
prefLabel
Triple negative tumours: a critical review.
@en
Triple negative tumours: a critical review.
@nl
P1433
P1476
Triple negative tumours: a critical review.
@en
P2093
A N J Tutt
J S Reis-Filho
P304
P356
10.1111/J.1365-2559.2007.02889.X
P577
2008-01-01T00:00:00Z